Compare
Quest Diagnostics Inc vs Labcorp Holdings Inc. vs Guardant Health, Inc. vs Veracyte, Inc.
| Latest fiscal year | Quest Diagnostics Inc DGX | Labcorp Holdings Inc. LH | Guardant Health, Inc. GH | Veracyte, Inc. VCYT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.04B | $13.95B | $982.02M | $517.14M |
| Revenue growth (YoY) | +11.8% | +7.2% | +32.9% | +16.0% |
| Gross margin | 33.2% (computed) | 28.8% | 64.5% (computed) | 70.1% |
| Operating margin | 14.1% | 9.9% | -44.5% | 11.2% |
| Net margin | 9.0% | 6.3% | -42.4% | 12.8% |
| Net income | $992.00M | $876.50M | -$416.28M | $66.35M |
| EPS (Diluted) | $8.75 | $10.46 | -$3.32 | $0.82 |
| Operating cash flow | $1.89B | $1.64B | -$184.76M | $136.31M |
| Free cash flow | $1.36B | $1.21B | -$233.07M | $126.63M |
| Cash & equivalents | $420.00M | $532.30M | $378.20M | $362.58M |
| Total assets | $16.23B | $18.39B | $2.01B | $1.41B |
| Total liabilities | n/a | $9.76B | $2.11B | $96.44M |
| Shareholders' equity | $7.21B | $8.62B | -$99.31M | $1.31B |
| Return on year-end equity | 13.8% | 10.2% | n/a | 5.1% |
| Shares outstanding | n/a | 82.20M | 130.64M | 79.36M |
Revenue, most recent five fiscal years
| Fiscal year | Quest Diagnostics Inc | Labcorp Holdings Inc. | Guardant Health, Inc. | Veracyte, Inc. |
|---|---|---|---|---|
| Latest | $11.04B Ended 2025-12-31 | $13.95B Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $517.14M Ended 2025-12-31 |
| 1 year earlier | $9.87B Ended 2024-12-31 | $13.01B Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $445.76M Ended 2024-12-31 |
| 2 years earlier | $9.25B Ended 2023-12-31 | $12.16B Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $361.05M Ended 2023-12-31 |
| 3 years earlier | $9.88B Ended 2022-12-31 | $11.86B Ended 2022-12-31 | $449.54M Ended 2022-12-31 | $296.54M Ended 2022-12-31 |
| 4 years earlier | $10.79B Ended 2021-12-31 | $13.14B Ended 2021-12-31 | $373.65M Ended 2021-12-31 | $219.51M Ended 2021-12-31 |